Replimune Group (NASDAQ: REPL)
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-05 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.580 | -0.600 | -0.0200 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Replimune Group (NASDAQ: REPL) through any online brokerage.
Other companies in Replimune Group’s space includes: Avidity Biosciences (NASDAQ:RNA), Syndax Pharmaceuticals (NASDAQ:SNDX), FibroGen (NASDAQ:FGEN), Kiniksa Pharmaceuticals (NASDAQ:KNSA) and Alector (NASDAQ:ALEC).
The latest price target for Replimune Group (NASDAQ: REPL) was reported by Wedbush on Tuesday, May 24, 2022. The analyst firm set a price target for 52.00 expecting REPL to rise to within 12 months (a possible 197.99% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Replimune Group (NASDAQ: REPL) is $17.45 last updated June 29, 2022, 8:00 PM UTC.
There are no upcoming dividends for Replimune Group.
Replimune Group’s Q1 earnings are confirmed for Friday, August 5, 2022.
There is no upcoming split for Replimune Group.
Replimune Group is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.